Albertsons climbs following Q2 results and FY21 guidance raise Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Dynavax (DVAX) up 5% after announcing that Valneva reported topline results from the Phase 3 pivotal trial of VLA2001, their inactivated COVID-19 vaccine candidate using Dynavax's CpG 1018 adjuvant
- Oyster Point Pharma (OYST) up 10% after announcing that that the FDA has approved Tyrvaya Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye disease
UP AFTER EARNINGS -
- Albertsons (ACI) up 5%
- State Street (STT) up 1%
DOWN AFTER EARNINGS -
LOWER -
- United Therapeutics (UTHR) down 1% after announcing the FDA issued a complete response letter declining to approve the Tyvaso NDA at this time
- Disney (DIS) down 2% after Barclays analyst Kannan Venkateshwar downgraded Disney to Equal Weight from Overweight with a price target of $175, down from $210
- Stellantis (STLA) down 2% after the company and and LG Energy Solution announced that their companies have entered into a memorandum of understanding to form a joint venture to produce battery cells and modules for North America
- Zilow (Z) down 8% after announcing that its Zillow Offers business will not sign any new, additional contracts to buy homes through the end of the year
- Revance (RVNC) down 35% after announcing that the FDA has determined it is unable to approve the DaxibotulinumtoxinA BLA in its present form, and indicated that there are deficiencies related to the FDA's onsite inspection at Revance's manufacturing facility
Symbols:
DVAX OYST ACI STT PHG UTHR DIS STLA Z RVNC ZG Keywords: Fly Intel, Wall Street, Top Stories, Stocks